US biopharmaceutical company OrthoTrophix Inc announced on Tuesday the early completion of the planned patient enrolment in its Phase 2b clinical trial of intra-articular TPX-100 for the treatment of knee osteoarthritis (OA).

The multicentre US trial began in May 2025 and is expected to complete in the first quarter of 2027.

TPX-100 is OrthoTrophix's lead therapeutic candidate, and is being developed as a potential disease-modifying osteoarthritis drug (DMOAD) -- designed not only to improve symptoms, but also to slow or halt disease progression.

In a prior randomised, placebo-controlled Phase 2a trial, TPX-100 was associated with a favourable safety profile and statistically significant improvements in knee function compared to placebo.

The Phase 2b trial is designed to further evaluate the clinical and structural findings observed in Phase 2a.